Annual Report FY 2004 - Research at Cornell

01. Tetragenetics, Inc., Brings IchVax Vaccine to Market

In recent years, the laboratory of Theodore G. Clark, Microbiology and Immunology, began exploring biotechnological applications of Tetrahymena thermophilia to over-express therapeutic proteins that are valuable for human and animal health. Tetrahymena is a single-celled organism, and it is the first animal-like cell to be grown in pure culture. It has long been a model for studies in molecular biology. Clark’s idea for the “TetraExpress” system won recognition as a finalist in the Business Idea Competition. With the help of a team of colleagues at University of Georgia and University of Rochester and entrepreneurs including alumnus R. Douglas Kahn, Clark founded Tetragenetics, Inc. The company’s first product, IchVax, is a vaccine to treat a well-known disease in fish. Efforts in strategic partnering are under way to develop a wider range of products that will include monoclonal antibodies, industrial enzymes, and reagent kits for the life science research market.

› Top  /  › Next Article  /  › Back to Listing


If you can see this message in a graphical web browser, then you are most likely using a non-modern browser. People who are using a graphical browser have the following options:

Upgrade to a modern generation web browser such as Mozilla, Opera, or for Mac users there is also Safari.

For people using early generation web browsers, such as Netscape 4, you can access the content of this page as is but there may be presentational errors.

Cornell University  
222 Day Hall
Ithaca, New York

P: 607.255.7200
F: 607.255.9030
E: VP Research
C: Credits